ClinicalTrials.gg
CompletedNCT07938437Updated Nov 16, 2026

5% Dextrose Prolotherapy Versus Dry Needling for Local Myalgia of the Masseter Muscle

A Phase 4 interventional study of 5% dextrose prolotherapy and Dry needling in Temporomandibular Disorders (TMDs) and Myalgia of Mastication Muscle, sponsored by Universidad de Los Andes, Venezuela. Completed at 1 site in Venezuela. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Universidad de Los Andes, Venezuela · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jul 2026, registered Nov 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial was to compare the pain-relieving effect of prolotherapy with 5% dextrose and dry needling in adults with local myalgia of the masseter muscle, a type of temporomandibular disorder (TMD). The main questions it aimed to answer were:

  • Does prolotherapy with 5% dextrose reduce pain immediately after treatment as much as dry needling?
  • How do pain intensity, the number of trigger points and adverse events change at 72 hours and 15 days after each treatment?

Participants were randomly assigned to one of two groups and received a single treatment session on the trigger points of the masseter muscles:

  • Prolotherapy group: injection of 0.5 mL of 5% dextrose into each trigger point.
  • Dry needling group: needling of each trigger point without injecting any substance.

Pain intensity and the number of trigger points were assessed before treatment, immediately after treatment, at 72 hours and at 15 days. Participants were asked to report any adverse event during follow-up.

Read the detailed description

This was a randomized, parallel-group clinical trial with 1:1 allocation, conducted at the Faculty of Dentistry, Universidad de Los Andes (Mérida, Venezuela), in accordance with the Declaration of Helsinki and the CONSORT statement. The trial was registered retrospectively.

Diagnosis of local myalgia was established by calibrated examiners according to the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD), using the TMD Symptom Questionnaire and the TMD Clinical Examination Form. A pilot test with four patients, not included in the final sample, was performed to assess feasibility and to calibrate the operator.

The sample size was calculated with G*Power 3.1.9.7 for a repeated-measures ANOVA with a treatment x time interaction (alpha = 0.05, power = 80%, f = 0.35, four measurements, correlation among measurements r = 0.50, nonsphericity correction = 1), yielding a minimum of 20 participants. Twenty-three participants were enrolled.

The allocation sequence was generated with Research Randomizer and concealed by an external collaborator not involved in clinical care. Masking of the operator and participants was not possible. The statistician was blinded to group allocation.

Trigger points in both masseter muscles were identified by digital palpation with approximately 1 kg of pressure for at least 2 seconds and marked on the skin. Prolotherapy was performed with a 31G needle and an insulin syringe, with a single insertion per trigger point. Dry needling was performed with sterile 0.25 mm acupuncture needles using Hong's fast-in, fast-out technique. All sessions lasted approximately 30 minutes. Participants were asked to avoid analgesics, physiotherapy, occlusal splints and self-medication during follow-up.

Adverse events were assessed according to CONSORT Harms 2022 and classified by MedDRA System Organ Class.

02

Conditions studied

  • Temporomandibular Disorders (TMDs)
  • Myalgia of Mastication Muscle

Keywords

  • Prolotherapy
  • Dextrose
  • Dry Needling
  • Local Myalgia
  • Trigger Points
  • Masseter Muscle
  • Orofacial Muscle Pain
  • Masticatory Muscle Disorders
03

In context

Temporomandibular Joint Disorders

593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

This study's enrollment of 23 is below the median of 45 across 417 interventional studies indexed under Temporomandibular Joint Disorders.

Browse Temporomandibular Joint Disorders studies →

Lead sponsor

This is the only study on the registry with Universidad de Los Andes, Venezuela as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults.
  • Clinical diagnosis of local myalgia-type temporomandibular disorder accordingto the DC/TMD.
  • Orofacial muscle pain lasting at least one week.
  • Signed after a detailed explanation of the study.

Exclusion criteria

Exclusion Criteria:

  • History of temporomandibular joint surgery or arthrocentesis, or current use of occlusal splints.
  • Previous diagnosis of fibromyalgia or systemic diseases affecting the anatomy or mechanical function of the temporomandibular joint.
  • History of allergic reactions to components of the injectable solution.
  • Open wounds, infections or dermatological diseases in the application area.
  • Pharmacological therapy (anti-inflammatory drugs, or psychotropic drugs) or physical therapy for muscle pain in the last month.
  • Previous diagnosis of psychiatric disorders.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Prolotherapy With 5% Dextrose

    Single session. Injection of 0.5 mL of 5% dextrose into each trigger point of both masseter muscles, with a 31G needle and a single insertion per trigger point.

    Drug: 5% dextrose prolotherapy

  • Active comparator
    Dry Needling

    Single session. Dry needling of each trigger point of both masseter muscles with 0.25 mm sterile acupuncture needles, using Hong's fast-in, fast-out technique, without injecting any substance.

    Procedure: Dry needling

Interventions

  • Drug5% dextrose prolotherapy

    Injection of 0.5 mL of 5% dextrose solution into each identified trigger point

  • ProcedureDry needling

    Repeated fast-in, fast-out needling of each identified trigger point without injectate.

06

What researchers measure

Primary outcomes

  1. Change in Pain Intensity Immediately After Treatment

    Pain intensity measured with a 0-10 Visual Analogue Scale (VAS; 0 = no pain, 10 = worst pain), expressed as the mean of both sides of the face. Change calculated as post-treatment minus baseline; negative values indicate pain reduction.

    Time frame: Baseline and immediately after treatment

Secondary outcomes

  1. Change in Pain Intensity at 72 Hours

    0-10 VAS, mean of both sides of the face. Change from baseline; negative values indicate pain reduction.

    Time frame: Baseline and 72 hours after treatment

  2. Change in Pain Intensity at 15 Days

    0-10 VAS, mean of both sides of the face. Change from baseline; negative values indicate pain reduction

    Time frame: Baseline and 15 days after treatment

  3. Change in Number of Trigger Points

    Total number of trigger points in both masseter muscles identified by digital palpation according to DC/TMD. Change from baseline; negative values indicate a reduction

    Time frame: Baseline, immediately after treatment, 72 hours and 15 days

  4. Number of Participants With Adverse Events

    Adverse events identified by active questioning at each visit and spontaneous reports, classified by MedDRA System Organ Class and characterized by type, severity and relationship to treatment.

    Time frame: From treatment to 15 day

07

Study locations

1 site
  • Facultad de Odontología, Universidad de Los Andes
    Mérida, Mérida 5101, Venezuela
08

References and documents

Publications

  • Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, List T, Svensson P, Gonzalez Y, Lobbezoo F, Michelotti A, Brooks SL, Ceusters W, Drangsholt M, Ettlin D, Gaul C, Goldberg LJ, Haythornthwaite JA, Hollender L, Jensen R, John MT, De Laat A, de Leeuw R, Maixner W, van der Meulen M, Murray GM, Nixdorf DR, Palla S, Petersson A, Pionchon P, Smith B, Visscher CM, Zakrzewska J, Dworkin SF; International RDC/TMD Consortium Network, International association for Dental Research; Orofacial Pain Special Interest Group, International Association for the Study of Pain. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Groupdagger. J Oral Facial Pain Headache. 2014 Winter;28(1):6-27. doi: 10.11607/jop.1151. PubMed 24482784 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data on pain intensity (VAS), number of trigger points, adverse events and sex will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Available from the publication of the study results, with no end date.

Access criteria: Data and supporting documents will be available upon reasonable request to the principal investigator by email.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Jul 2026, 0 months.

Of 11 phase 4 interventional studies under Temporomandibular Joint Disorders, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 23. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Jul 31, 2026
Primary completionActual
Jul 31, 2026
CompletionActual
Aug 14, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938437
Lead sponsor
Universidad de Los Andes, Venezuela
Responsible party
Julio Medina (Postgraduate Resident in Oral Rehabilitation, Universidad de Los Andes, Venezuela) — Principal investigator
First posted
Nov 16, 2026
Start date
Jul 31, 2026
Primary completion
Jul 31, 2026
Completion
Aug 14, 2026
Last update
Nov 16, 2026

Study contacts

Julio C Medina, DDS
principal investigator · Universidad de Los Andes, Venezuela

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion